Risedronate pharmacokinetics following daily (5 mg/day) and weekly (35 and 50 mg/week) oral dosing regimens to postmenopausal women.

被引：0
|
作者：
Burgio, D
Russell, D
Desliva, B
Namour, F
Thompson, G
机构：
[1] P&G Pharmaceut, Romainville, France
[2] Aventis Pharma, Mason, OH USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2002年 / 71卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：P32 / P32
页数：1
相关论文
共 20 条
  • [1] Risedronate 35 mg once a week is as effective as 5 mg daily in postmenopausal women.
    Lindsay, R
    Kendler, D
    McClung, MR
    Balske, A
    Li, ZQ
    Brown, J
    [J]. ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S153 - S153
  • [2] Comparison of daily (5 MG/DAY and 15 MG/DAY) oral dosing regimens of risedronate to healthy male and female volunteers.
    Burgio, DE
    Sun, LA
    Russell, DA
    Whitham, DJ
    Eusebio, R
    Thompson, GA
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (02) : P49 - P49
  • [3] Efficacy and acceptability of risedronate 5 mg daily compared with 35 mg once weekly for the treatment of postmenopausal osteoporosis
    Ilter, E
    Karalok, H
    Tufekci, EC
    Batur, O
    [J]. CLIMACTERIC, 2006, 9 (02) : 129 - 134
  • [4] Once-a-week (35 mg) risedronate is as effective as daily (5 mg)
    Lindsay, R
    Adachi, JD
    Emkey, RD
    Li, Z
    Balske, A
    Brown, J
    [J]. OSTEOPOROSIS INTERNATIONAL, 2002, 13 : S16 - S16
  • [5] Oral risedronate 150 mg once monthly is as effective as oral daily 5 mg risedronate in postmenopausal osteoporosis: Phase II results.
    Ste-Marie, L.
    Brown, J. P.
    Beary, J. F.
    Darbie, L.
    Burgio, D. E.
    Racewicz, A.
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 : S111 - S111
  • [6] Monthly dosing with risedronate 50 mg on three consecutive days a month compared with daily dosing with risedronate 5 mg: a 6-month pilot study
    Racewicz, Artur J.
    Schofield, Pamela J.
    Cahall, David L.
    Cline, Gary A.
    Burgio, David E.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (12) : 3079 - 3089
  • [7] Once-a-month 150 mg oral risedronate is as effective as oral daily 5 mg risedronate in postmenopausal osteoporosis: Phase II study results
    Ste-Marie, L. G.
    Brown, J. P.
    Beary, J. F.
    Darbie, L.
    Burgio, D. E.
    Racewicz, A.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S210 - S211
  • [8] The efficacy and safety of weekly 35-mg risedronate dosing regimen for Chinese postmenopausal women with osteoporosis or osteopenia: 1-year data
    Gu, Jie-mei
    Wang, Li
    Lin, Hua
    Chen, De-cai
    Tang, Hai
    Jin, Xiao-lan
    Xia, Wei-bo
    Hu, Yun-qiu
    Fu, Wen-zhen
    He, Jin-wei
    Zhang, Hao
    Wang, Chun
    Yue, Hua
    Hu, Wei-wei
    Liu, Yu-juan
    Zhang, Zhen-lin
    [J]. ACTA PHARMACOLOGICA SINICA, 2015, 36 (07) : 841 - 846
  • [9] The efficacy and safety of weekly 35-mg risedronate dosing regimen for Chinese postmenopausal women with osteoporosis or osteopenia: 1-year data
    Jie-mei Gu
    Li Wang
    Hua Lin
    De-cai Chen
    Hai Tang
    Xiao-lan Jin
    Wei-bo Xia
    Yun-qiu Hu
    Wen-zhen Fu
    Jin-wei He
    Hao Zhang
    Chun Wang
    Hua Yue
    Wei-wei Hu
    Yu-juan Liu
    Zhen-lin Zhang
    [J]. Acta Pharmacologica Sinica, 2015, 36 : 841 - 846
  • [10] Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: A randomized double-blind study
    Rosen, CJ
    Hochberg, MC
    Bonnick, SL
    McClung, M
    Miller, P
    Broy, S
    Kagan, R
    Chen, E
    Petruschke, RA
    Thompson, DE
    de Papp, AE
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (01) : 141 - 151
12